ClinicalTrials.gg
CompletedNCT00662883Updated Apr 22, 2008

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

A Phase 1 interventional study of PMI-150 (intranasal ketamine HCl); mometasone furoate in Healthy, sponsored by Javelin Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-04-22.

Sponsored by Javelin Pharmaceuticals · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal absorption of PMI-150 (intranasal ketamine HCl)

Read the detailed description

Subjects will participate in a two-period, single-sequence study to assess the effects of administration of a nasal corticosteroid, Nasonex (mometasone furoate), on the pharmacokinetics, safety and tolerability of PMI-150 (intranasal ketamine HCl) in healthy adult volunteers.

02

Conditions studied

  • Healthy

Keywords

  • ketamine
  • corticosteroid
  • intranasal
  • phase I
  • Healthy volunteers
03

In context

Lead sponsor

Javelin Pharmaceuticals is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy adults
  • nonsmoker
  • no drug use

Exclusion criteria

Exclusion Criteria:

  • nasal abnormalities
  • airway abnormalities
05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    A

    * PMI-150 (intranasal ketamine HCl), day 1 * mometasone furoate, days 2-15 * PMI-150 (intranasal ketamine HCl), day 15

    Drug: PMI-150 (intranasal ketamine HCl); mometasone furoate

Interventions

  • DrugPMI-150 (intranasal ketamine HCl); mometasone furoate

    Drug pages: Ketamine · Mometasone Furoate

    * 1 dose PMI-150 (intranasal ketamine HCl); day 1 * mometasone furoate, daily; days 2-15 * 1 dose PMI-150 (intranasal ketamine HCl); day 15

    Also known as: Nasonex

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters

    Time frame: 15 days

07

Study locations

1 site
  • Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2008
First posted
Apr 21, 2008
Start
Nov 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
Apr 22, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00662883
Lead sponsor
Javelin Pharmaceuticals
First posted
Apr 21, 2008
Start date
Nov 2007
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Apr 22, 2008

Study contacts

Javelin Pharmaceuticals, Inc
study director · Javelin Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Mometasone Furoate

Start the discussion